Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection

Transplant Infectious Disease

Volumn 16, Issue 2, 2014, Pages 295-303

  Cho, J H ^a,b   Lim, J H ^a,b   Park, G Y ^a,b   Kim, J S ^a,b   Kang, Y J ^a,b   Kwon, O ^a,b   Choi, J Y ^a,b   Park, S H ^a,b   Kim, Y L ^a,b   Kim, H K ^c   Huh, S ^c   Kim, C D ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Clinical Research Center for End Stage Renal Disease   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

Author keywords

Antiviral treatment; Hepatitis B virus; Kidney transplantation; Withdrawal

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CREATININE; CYCLOSPORIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; TELBIVUDINE; VIRUS DNA; ADENINE; GUANINE; PHOSPHONIC ACID DERIVATIVE; THYMIDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; FOLLOW UP; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; TIME; TREATMENT WITHDRAWAL; VIRUS ACTIVATION;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; THYMIDINE; TIME FACTORS; VIRUS ACTIVATION; WITHHOLDING TREATMENT;

EID: 84897959215     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12202     Document Type: Article

References (35)

1. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62: 297-299.
2. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007; 20: 440-451.
3. Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation 2008; 86: 784-790.
4. Murakami R, Amada N, Sato T, et al. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience. Clin Transplant 2006; 20: 351-358.
5. Lee WC, Shu KH, Cheng CH, et al. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001; 21: 300-306.
6. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
7. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-2921.
8. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77: 859-864.
9. Lee W-C, Wu M-J, Cheng C-H, et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38: 1074-1081.
10. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-748.
11. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
12. Yap DYH, Tang CSO, Yung S, et al. Long-term outcome of renal transplant recipients with chronic hepatitis b infection-impact of antiviral treatments. Transplantation 2010; 90: 325-330.
13. Cosconea S, Fontaine H, Meritet JF, et al. Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol 2012; 57: 55-60.
14. Rostaing L, Henry S, Cisterne JM, et al. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624-1627.
15. Goffin E, Horsmans Y, Cornu C, Squifflet JP, Pirson Y. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation 1998; 66: 407-409.
16. Chan TM, Tse KC, Tang CSO, Lai KN, Ho SKN. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004; 4: 1103-1109.
17. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174-S184.
18. Levitsky J, Doucette K. Viral hepatitis in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 147-168.
19. Kidney Disease: Improving Global Outcome (KDIGO) Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1-S155.
20. Chan T, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SH. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-1252.
21. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
22. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
23. Huang YW, Liu CJ, Lai MY, et al. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: a retrospective case series. Clin Ther 2006; 28: 1327-1334.
24. Hu T-H, Tsai M-C, Chen Y-T, et al. The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. Hepatol Int 2011; 6: 449-456.
25. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-1087.
26. Karayiannis P, Fowler MJ, Lok AS, et al. Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol 1985; 1: 99-106.
27. Liaw YF, Chen JJ, Chen TJ. Acute exacerbation in patients with liver cirrhosis: a clinicopathological study. Liver 1990; 10: 177-184.
28. Myers RP, Chaudhary R, Fonseca K, Lee SS. Fatal hepatic decompensation in a patient with hepatitis B cirrhosis following famciclovir withdrawal. Can J Gastroenterol 2000; 14: 725-727.
29. Fontaine H, Vallet-Pichard A, Chaix ML, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80: 1086-1092.
30. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
31. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
32. Honkoop P, de Man RA, Niesters HGM, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-639.
33. Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-614.
34. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
35. Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012; 18: 109-162.